

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Launches LEUPRORELIN ACETATE SR FOR INJECTION KIT

TOKYO, December 4, 2025 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), announced today that an LH-RH derivative microcapsule-type sustained-release agent, LEUPRORELIN ACETATE SR FOR INJECTION KIT (generic name: leuporelin) has been listed in the NHI (National Health Insurance) drug price list today, and is to be launched on December 5, the effective date of the NHI drug price list.

The impact of this matter on the Company's business performance has already been incorporated into the full-year consolidated earnings forecast for FY2025.

.Overview of LEUPRORELIN ACETATE SR FOR INJECTION KIT

Product name: LEUPRORELIN ACETATE SR FOR INJECTION KIT

Generic name: Leuporelin acetate for injection

Indication: - Prostate cancer
 - Premenopausal breast cancer

Dosage and The usual adult dosage is 11.25 mg of leuporelin acetate administered
Administration : subcutaneously once every 12 weeks.

To administer, push the plunger rod with the needle up and transfer the entire suspension solution to the powder section and suspend it thoroughly, taking care not to foam.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp